Abstract
Sweet syndrome, pyoderma gangrenosum, and subcorneal pustular dermatosis are neutrophilic dermatoses – conditions that have an inflammatory infiltrate consisting of mature polymorphonuclear leukocytes. The neutrophils are usually located within the dermis in Sweet syndrome and pyoderma gangrenosum; however, in subcorneal pustular dermatosis, they are found in the upper layers of the epidermis. Sweet syndrome, also referred to as acute febrile neutrophilic dermatosis, is characterized by pyrexia, elevated neutrophil count, painful erythematous cutaneous lesions that have an infiltrate of mature neutrophils typically located in the upper dermis, and prompt clinical improvement following the initiation of systemic corticosteroid therapy. Classical, malignancy-associated, and drug-induced variants of Sweet syndrome exist. Pyoderma gangrenosum is characterized by painful, enlarging necrotic ulcers with bluish undermined borders surrounded by advancing zones of erythema; its clinical variants include: ulcerative or classic, pustular, bullous or atypical, vegetative, peristomal, and drug-induced. Subcorneal pustular dermatosis is an uncommon relapsing symmetric pustular eruption that involves flexural and intertriginous areas; it can be idiopathic or associated with cancer, infections, medications, and systemic diseases. Since Sweet syndrome, pyoderma gangrenosum, and subcorneal pustular dermatosis share not only the same inflammatory cell but also similar associated systemic diseases, it is not surprising that the concurrent or sequential development of these neutrophilic dermatoses has been observed in the same individual. Also, it is not unexpected that several of the effective therapeutic interventions – including systemic drugs, topical agents, and other treatment modalities – for the management of these dermatoses are the same.
The treatment of choice for Sweet syndrome and idiopathic pyoderma gangrenosum is systemic corticosteroids; however, for subcorneal pustular dermatosis, dapsone is the drug of choice. Yet, tumor necrosis factor-α antagonists are becoming the preferred choice when pyoderma gangrenosum is accompanied by inflammatory bowel disease or rheumatoid arthritis. Potassium iodide and colchicine are alternative first-line therapies for Sweet syndrome and indomethacin (indometacin), clofazimine, cyclosporine (ciclosporin), and dapsone are second-line treatments. Cyclosporine is effective in the acute management of pyoderma gangrenosum; however, when tapering the drug, additional systemic agents are necessary for maintaining the clinical response. In some patients with subcorneal pustular dermatosis, systemic corticosteroids may be effective; yet, systemic retinoids (such as etretinate and acitretin) have effectively been used for treating this neutrophilic dermatosis – either as monotherapy or in combination with dapsone or as a component of phototherapy with psoralen andUVAradiation. Topical agents can have an adjuvant role in themanagement of these neutrophilic dermatoses; however, high-potency topical corticosteroids may successfully treat localized manifestations of Sweet syndrome, pyoderma gangrenosum, and subcorneal pustular dermatosis. Intralesional corticosteroid therapy for patients with Sweet syndrome and pyoderma gangrenosum, hyperbaric oxygen and plasmapheresis for patients with pyoderma grangrenosum, and phototherapy for patients with subcorneal pustular dermatosis are other modalities that have been used effectively for treating individuals with these neutrophilic dermatoses.
Similar content being viewed by others
References
Cohen PR. Neutrophilic dermatoses occurring in oncology patients. Int J Dermatol 2007; 46: 106–11
Callen JP. Neutrophilic dermatoses. Dermatol Clin 2002; 20: 409–19
Cohen PR. Sweet’s syndrome: a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2: 34
Cohen PR, Almeida L, Kurzrock R. Acute febrile neutrophilic dermatosis. Am Fam Physician 1989; 39 (3): 199–204
Cohen PR, Kurzrock R. Diagnosing the Sweet syndrome. Ann Intern Med 1989; 110: 573–4
Cohen PR, Kurzrock R. Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol 2000; 18: 265–82
Cohen PR, Kurzrock R. The pathogenesis of Sweet’s syndrome [letter]. J Am Acad Dermatol 1991; 25: 734
Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol 2003; 42: 761–78
Cohen PR. Preganancy-associated Sweet’s syndrome: world literature review. Obstet Gynecol Survey 1993; 48: 584–7
Satra KH, Zalka A, Cohen PR, et al. Sweet’s syndrome and pregnancy. J Am Acad Dermatol 1994; 30: 297–300
Cohen PR, Kurzrock R. Sweet’s syndrome and cancer. Clin Dermatol 1993; 11: 149–57
Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet’s syndrome: review of the world literature. J Clin Oncol 1988; 6: 1887–97
Cohen PR, Kurzrock R. Chonic myelogenous leukemia and Sweet syndrome. Am J Hematol 1989; 32: 134–7
Cohen PR, Kurzrock R. Paraneoplastic Sweet’s syndrome. Emerg Med 1994; 26 (2): 37–8
Cohen PR, Kurzrock R. Sweet’s syndrome and malignancy. Am J Med 1987; 82: 1220–6
Cohen PR, Holder WR, Tucker SB, et al. Sweet syndrome in patients with solid tumors. Cancer 1993; 72: 2723–31
Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol 1996; 34: 918–23
Cohen PR. Skin lesions of Sweet syndrome and its dorsal hand variant contain vasculitis: an oxymoron or an epiphenomenon? Arch Dermatol 2002; 138: 400–3
Cohen PR. Subcutaneous Sweet’s syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. J Am Acad Dermatol 2005; 52: 927–8
Cohen PR, Holder WR, Rapini RP. Concurrent Sweet’s syndrome and erythema nodosum: a report, world literature review and mechanism of pathogenesis. J Rheumatol 1992; 19: 814–20
Cohen PR. Sweet’s syndrome presenting as conjunctivitis. Arch Ophthalmol 1993; 111: 587–8
Cohen PR, Kurzrock R. Extracutaneous manifestations of Sweet’s syndrome: steroid-responsive culture-negative pulmonary lesions [letter]. Am Rev Respir Dis 1992; 146: 269
Cohen PR. Sweet syndrome and erythema nodosum [letter]. South Med J 2007; 100: 1057–8
Cohen PR. Sweet’s syndrome and relapsing polychondritis: is their appearance in the same patient a coincidental occurrence or a bona fide association of these conditions? Int J Dermatol 2004; 43: 772–7
Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007; 33: 787–803
Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 333: 181–4
Wollina U. Pyoderma gangrenosum: a review. Orphanet J Rare Dis 2007; 2: 19
Powell FC, Collins S. Pyoderma gangrenosum. Clin Dermatol 2000; 18: 283–93
Crowson AN, Mihm Jr MC, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003; 30: 97–107
Reed J, Wilkinson J. Subcorneal pustular dermatosis. Clin Dermatol 2000; 18: 301–13
Bordignon M, Zattra E, Montesco MC, et al. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) with absence of desmoglein 1 and 3 antibodies case report and literature review. Am J Clin Dermatol 2008; 9: 51–5
Cheng S, Edmonds E, Ben-Gashir M, et al. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol 2008; 33: 229–33
Castro-Fernandez M, Sanchez-Munos D, Ruiz-Granados E, et al. Coexistence of pyoderma gangrenosum and Sweet’s syndrome in a patient with ulcerative colitis [letter]. Am J Gastroenterol 2007; 102: 2865–6
Caughman W, Stern R, Haynes H. Neutrophilic dermatosis of myeloproliferative disorders. J Am Acad Dermatol 1983; 9: 751–8
Lear JT, Byrne JPH. Bullous pyoderma gangrenosum, Sweet’s syndrome and malignancy [letter]. Br J Dermatol 1997; 136: 296–7
Salmon P, Rademaker M, Edwards L. A continuum of neutrophilic disease occurring in a patient with ulcerative colitis. Australas J Dermatol 1998; 39: 116–8
Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis: an extracutaneous neutrophilic disorder. Report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet’s syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol 1999; 40: 331–4
Marsden JR, Millard LG. Pyoderma gangrenosum, subcorneal pustular dermatosis and IgA paraproteinaemia. Br J Dermatol 1986; 114: 125–9
Kohl PK, Hartschuh W, Tilgen W, et al. Pyoderma gangrenosum followed by subcorneal pustular dermatosis in a patient with IgA paraproteinemia. J Am Acad Dermatol 1991; 24: 325–8
Cartier H, Plantin P, Leroy JP, et al. Pyoderma gangrenosum, subcorneal IgA pustulosis and recurrent neutrophilic pleural and pulmonary disease in a patient with IgA gammopathy. Ann Dermatol Venereol (Paris) 1995; 122: 97–101
Freire Murgueytio P, Allegue F, Martin Gonzalez M, et al. Gangrenous pyoderma associated with subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Med Cutan Ibero Lat Am 1989; 17: 105–9
Venning VA, Ryan TJ. Subcorneal pustular dermatosis followed by pyoderma gangrenosum. Br J Dermatol 1986; 115: 117–8
Puechguiral-Renaud I, Carpentier O, Piette F, et al. Subcorneal pustulosis and pyoderma gangrenosum associated with a biclonal gammopathy. Eur J Dermatol 2006; 16: 687–90
Scerri L, Zaki I, Allen BR. Pyoderma gangrenosum and subcorneal pustular dermatosis, without monoclonal gammopathy. Br J Dermatol 1994; 130: 398–9
Wolff K. Subcorneal pustulose dermatose (Sneddon-Wilkinson): pyoderma gangrenosum mit IgA paraproteinamie [abstract]. Dermatol Wocherschrift 1971; 157: 842
Dallot A, Decazes JM, Drouault Y, et al. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) with amicrobial lymph node suppuration and aseptic spleen abscess. Br J Dermatol 1988; 119: 803–7
Cohen PR, Kurzrock R. Sweet’s syndrome: a review of current treatment options. Am J Clin Dermatol 2002; 3: 117–31
Cohen PR, Holder WR. Pentoxifylline for Sweet’s syndrome. J Am Acad Dermatol 1995; 32: 533–4
Cohen PR, Kurzrock R. Treatment of Sweet’s syndrome [letter]. Am J Med 1990; 89: 396
Delluc A, Limal N, Puechal X, et al. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008; 67: 278–9
Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273–83
Gettler S, Rothe M, Grin C, et al. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol 2003; 4: 597–608
Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006; 5: e8
Juillerat P, Christen-Zach S, Troillet F-X, et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis: case report and literature review. Dermatology 2007; 215: 245–51
Chiba T, Isomura I, Suzuki A, et al. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005; 32: 199–203
Foss CE, Clark AR, Inabinet R, et al. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008 Aug; 22: 943–9
Meyer N, Ferraro V, Mignard M-H, et al. Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: two cases and review of the literature. Clin Drug Invest 2006; 26: 541–6
Cummins DL, Anhalt GJ, Monahan T, et al. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 2007; 157: 1235–9
Wenzel J, Gerdsen R, Phillipp-Dormston W, et al. Topical treatment of pyoderma gangrenosum. Dermatology 2002; 205: 221–3
Tutrone WD, Green K, Weinberg JM, et al. Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy. J Drugs Dermatol 2007; 6: 1214–9
Marliere V, Beylot-Barry M, Beylot C, et al. Successful treatment of subcorneal pustular dermatosis (Sneddon-Wilkinson disease) by acitretin: report of a case. Dermatology 1999; 199: 153–6
Voigtlander C, Luftl M, Schuler G, et al. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001; 137: 1571–4
Bonifati C, Trento E, Cordiali Fei P, et al. Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol 2005; 30: 662–5
Kawaguchi M, Mitsuhashi Y, Kondo S. A case of subcorneal pustular dermatosis treated with tacalcitol (1alpha, 24-dihydroxyvitaminD3). J Dermatol 2000; 27: 669–72
Acknowledgments
No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cohen, P.R. Neutrophilic Dermatoses. AM J Clin Dermatol 10, 301–312 (2009). https://doi.org/10.2165/11310730-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11310730-000000000-00000